Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Exploratory Study of Low Dose Psilocybin

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05227742
Recruitment Status : Not yet recruiting
First Posted : February 7, 2022
Last Update Posted : May 13, 2022
Sponsor:
Collaborator:
Diamond Therapeutics Inc.
Information provided by (Responsible Party):
Peter Hendricks, University of Alabama at Birmingham

Tracking Information
First Submitted Date  ICMJE January 13, 2022
First Posted Date  ICMJE February 7, 2022
Last Update Posted Date May 13, 2022
Estimated Study Start Date  ICMJE August 2022
Estimated Primary Completion Date December 2022   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: January 26, 2022)
  • Demoralization [ Time Frame: Study Termination at Week 8 ]
    Demoralization as assessed by the Demoralization Scale-II (DS-II; possible range = 0 to 32, with higher scores reflecting worse outcomes)
  • Mystical Experience [ Time Frame: At the conclusion of Drug Administration #1 at Week 3 ]
    Mystical experience as assessed by the Mystical Experience Questionnaire (MEQ; possible range = 0 to 5, with higher scores reflecting more mystical experience)
  • Mystical Experience [ Time Frame: At the conclusion of Drug Administration #2 at Week 4 ]
    Mystical experience as assessed by the Mystical Experience Questionnaire (MEQ; possible range = 0 to 5, with higher scores reflecting more mystical experience)
  • Mystical Experience [ Time Frame: At the conclusion of Drug Administration #3 at Week 5 ]
    Mystical experience as assessed by the Mystical Experience Questionnaire (MEQ; possible range = 0 to 5, with higher scores reflecting more mystical experience)
  • Mystical Experience [ Time Frame: At the conclusion of Drug Administration #4 at Week 6 ]
    Mystical experience as assessed by the Mystical Experience Questionnaire (MEQ; possible range = 0 to 5, with higher scores reflecting more mystical experience)
  • Mystical Experience [ Time Frame: At the conclusion of Drug Administration #5 at Week 7 ]
    Mystical experience as assessed by the Mystical Experience Questionnaire (MEQ; possible range = 0 to 5, with higher scores reflecting more mystical experience)
  • Challenging Experience [ Time Frame: At the conclusion of Drug Administration #1 at Week 3 ]
    Challenging experience as assessed by the Challenging Experience Questionnaire (CEQ; possible range = 0=5, with higher scores reflection more challenging experiences)
  • Challenging Experience [ Time Frame: At the conclusion of Drug Administration #2 at Week 4 ]
    Challenging experience as assessed by the Challenging Experience Questionnaire (CEQ; possible range = 0=5, with higher scores reflection more challenging experiences)
  • Challenging Experience [ Time Frame: At the conclusion of Drug Administration #3 at Week 5 ]
    Challenging experience as assessed by the Challenging Experience Questionnaire (CEQ; possible range = 0=5, with higher scores reflection more challenging experiences)
  • Challenging Experience [ Time Frame: At the conclusion of Drug Administration #4 at Week 6 ]
    Challenging experience as assessed by the Challenging Experience Questionnaire (CEQ; possible range = 0=5, with higher scores reflection more challenging experiences)
  • Challenging Experience [ Time Frame: At the conclusion of Drug Administration #5 at Week 7 ]
    Challenging experience as assessed by the Challenging Experience Questionnaire (CEQ; possible range = 0=5, with higher scores reflection more challenging experiences)
  • PASAT [ Time Frame: At hour 2 of Drug Administration #3 at Week 5 ]
    Executive functioning as assessed by the Paced Auditory Serial Addition Test (PASAT)
  • Trail Making [ Time Frame: At hour 2 of Drug Administration #4 at Week 6 ]
    Executive functioning as assessed by the Delis-Kaplan Trail Making Test
  • CPT-3 [ Time Frame: At hour 2 of Drug Administration #5 at Week 7 ]
    Attention and cognitive control as assessed by Conner's Continuous Performance Test (CPT-3)
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE Not Provided
Original Secondary Outcome Measures  ICMJE Not Provided
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Exploratory Study of Low Dose Psilocybin
Official Title  ICMJE Exploratory Study of the Effects of Low-Dose Psilocybin on Sensory Processing, Neurophysiological Arousal, and Emotional Health
Brief Summary The purpose of the present study is to evaluate the feasibility, initial signals of efficacy, and potential mechanisms of action of "microdoses" of psilocybin (i.e., low doses of psilocybin that are not believed to produce mystical-type, transcendent, hallucinogenic, or other overtly salient subjective effects that limit functionality) in the treatment of moderate to severe demoralization (feelings of hopelessness and meaningless that frequently accompany medical illness and other life hardship).
Detailed Description

Individuals who call research staff will undergo an initial telephone screen that will determine eligibility.

Week 1: Baseline Intake Appointment. Those who are eligible to participate on the basis of the telephone screen and provide informed consent will then complete a standard demographic questionnaire, a detailed psychiatric interview, and provide a urine sample for confirmation of substance abstinence and pregnancy status. Participants will then be administered a detailed medical history interview and physical examination including EKG and blood panel.

Week 2: Orientation. Participants who are medically eligible to participate will be scheduled for a psychoeducational orientation session that further explains the rationale of the study, and summarizes the study logistics. Participants will complete a number of baseline questionnaires and neuropsychological assessments at this time.

Week 3: Drug administration #1. In a between-groups design, participants will be randomized to receive 0 mg, 1 mg, 2.5 mg, or 5 mg of psilocybin at five weekly 6-hour long drug administration sessions. Dose will remain constant for each participant at each drug administration session.

At Drug Administration #1 and all subsequent drug administration sessions, participants will complete visual analogue scale (VAS) questions drawn from different sources that include drug abuse liability measures. These VAS questions will be administered at drug administration baseline and every 30 minutes thereafter through the end of acute effects at 6-hrs post-baseline. Research staff will complete a number of observational assessments at similar intervals.

Blood pressure will be assessed at regular intervals via automatic blood pressure monitor (i.e., at baseline and at 30, 60, 90, 120, 180, 240, and 360 min post-baseline), and medication for the treatment of acute hypertension will be administered should blood pressure exceed 200 systolic and/or 110 diastolic.

At peak drug effects (2 hr post-baseline), a number of measures will be administered, each differing by drug administration session. At Drug Administration #1, participants will undergo two electroencephalogram (EEG) tasks (with assessments at baseline serving as pre-drug control values).

At 6-hr post-baseline, participants will complete self-report measures assessing the subjective experience. These questionnaires will be administered at the conclusion of each drug administration session. Participants will then be administered a brief semi-structured qualitative interview designed to probe the nature of their experience. All participants will be required to arrange for transportation home from the CRU; participants will not be allowed to drive themselves after drug administration sessions.

Week 4: Drug Administration #2. This session will be identical to Drug Administration #1, however, at peak drug effects, participants will complete two new EEG tasks (with assessments at baseline serving as pre-drug control values).

Week 5: Drug Administration #3. This session will be identical to prior drug administration sessions, however, at peak drug effects, a neuropsychological measure will be administered.

Week 6: Drug Administration #4. This session will be identical to prior drug administration sessions, however, at peak drug effects, participants will complete another neuropsychological measure.

Week 7: Drug Administration #5. This session will be identical to prior drug administration sessions, however, at peak drug effects, participants will complete another neuropsychological measure. At the conclusion of this measure, subjects will undergo an EEG assessment (with an assessment at baseline serving as a pre-drug control value).

Week 8: Study Termination. This session will comprise completion of the same questionnaires that were previously completed at baseline as well as a semi-structured qualitative interview. EKG will be repeated at study termination.

It is noted that over the duration of the study, every day participants will be asked to complete some brief self-report measures and a resting state EEG via a smartphone app.

Study Type  ICMJE Interventional
Study Phase  ICMJE Early Phase 1
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:
This is a double-blind, placebo-controlled clinical trial.
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Condition  ICMJE Demoralization
Intervention  ICMJE
  • Drug: Psilocybin
    Participants will receive oral psilocybin once per week for 5 weeks.
  • Drug: Placebo
    Participants will receive inert placebo once per week for 5 weeks.
Study Arms  ICMJE
  • Placebo Comparator: Placebo (0 mg psilocybin)
    Participants in this arm will receive 0 mg of psilocybin once per week for 5 weeks.
    Intervention: Drug: Placebo
  • Experimental: 1 mg psilocybin
    Participants in this arm will receive 1 mg psilocybin once per week for 5 weeks.
    Intervention: Drug: Psilocybin
  • Experimental: 2.5 mg psilocybin
    Participants in this arm will receive 2.5 mg psilocybin once per week for 5 weeks.
    Intervention: Drug: Psilocybin
  • Experimental: 5 mg psilocybin
    Participants in this arm will receive 5 mg psilocybin once per week for 5 weeks.
    Intervention: Drug: Psilocybin
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Not yet recruiting
Estimated Enrollment  ICMJE
 (submitted: January 26, 2022)
60
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE March 2023
Estimated Primary Completion Date December 2022   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Ability to read and write in English
  2. Between 25 and 65 years old
  3. Demoralization Scale-II (DS-II) score of > 8
  4. No prior hallucinogen use or it would have been 3 years since the last use of a hallucinogen
  5. Availability of a friend, family member, or other form of transportation (e.g., Uber) to drive participants home after their drug administration sessions
  6. In good general health as assessed by detailed medical history interview and physical examination

Exclusion Criteria:

  1. 24 years of age or younger; 66 years of age or older
  2. Women who are pregnant (pregnancy status confirmed via urine pregnancy test) or breastfeeding
  3. Current hypertension (exceeding 140 systolic and/or 90 diastolic at resting)
  4. Use of methylphenidate or other medications for ADHD, benzodiazepines or other medications for anxiety (e.g., beta-blockers), tricyclic antidepressants, MAOIs, SSRIs, SNRIs or other medications for depression, lithium or other mood stabilizers, haloperidol or other antipsychotic medications, any medications or supplements with serotonin activity (e.g., St. John's Wort), or any other pharmacologic or biologic agent used to treat depression or anxiety (e.g., magnesium, cannabis)
  5. Personal or family history (first or second degree relatives) of psychotic or bipolar I or II disorders
  6. Any suicidal ideation of type 4 or type 5 on the Columbia Suicide Severity Rating Scale (C-SSRS) in the 3 months prior to screening (i.e., active suicidal thought with method and intent but without a specific plan, or active suicidal thought with method, intent and plan).
  7. History of head trauma, loss of consciousness, or neurological disease
  8. Receiving treatment within the past 30 days for depression, anxiety, or substance use disorder
  9. Participation within the past 30 days in a clinical trial for the treatment of depression, anxiety, or substance use disorder
  10. Any current substance use disorder diagnosis (substance abstinence confirmed via urine drug screen)
  11. History of immoderate alcohol consumption within the past 3 months per NIAAA definitions: more than 4 drinks per day or 14 drinks per week for men; more than 3 drinks per day or 7 drinks per week for women
  12. Any headache disorder (i.e., migraine, tension-type headache, or cluster headache) in the past year
  13. Planning to move from the Birmingham area in the next 3 months
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 25 Years to 65 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE
Contact: Peter S Hendricks, PhD 205.202.1387 phendricks@uab.edu
Listed Location Countries  ICMJE Not Provided
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT05227742
Other Study ID Numbers  ICMJE IRB-300008551
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
IPD Sharing Statement  ICMJE Not Provided
Current Responsible Party Peter Hendricks, University of Alabama at Birmingham
Original Responsible Party Same as current
Current Study Sponsor  ICMJE University of Alabama at Birmingham
Original Study Sponsor  ICMJE Same as current
Collaborators  ICMJE Diamond Therapeutics Inc.
Investigators  ICMJE Not Provided
PRS Account University of Alabama at Birmingham
Verification Date March 2022

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP